Hostname: page-component-84b7d79bbc-rnpqb Total loading time: 0 Render date: 2024-07-26T12:17:09.161Z Has data issue: false hasContentIssue false
  • English
  • Français

Sustained Release Antiparkinson Agents: Controlled Release Levodopa

Published online by Cambridge University Press:  18 September 2015

Serge Gauthier  and
Donna Amyot
Serge Gauthier*
Affiliation:
McGill Centre for Studies in Aging, Montreal
Donna Amyot
Affiliation:
McGill Centre for Studies in Aging, Montreal
*
McGill Centre for Studies in Aging, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The rationale for sustained release oral levodopa preparations is to deliver levodopa in the areas of maximal intestinal absorption in a slow and predictable way, leading to stable plasma levodopa levels and brain dopamine levels, therefore resulting in a lengthened duration of action. Sinemet CR is the prototype of such preparations, with demonstrated efficacy in decreasing periods of akinesia in parkinsonian patients with mild to moderate motor fluctuations. Total doses of levodopa are raised 10 to 30% because of the lowered bioavailability; diphasic dyskinesias may increase at the end of the day. Tolerance is good in de novo patients and studies are in progress to establish if early treatment with Sinemet CR delays the onset or attenuates the severity of motor fluctuations as compared to standard Sinemet.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue S1: 3rd Canadian Conference on Neurodegenerative Diseases , February 1992 , pp. 153 - 155
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Fahn, S.Fluctuations of disability in PD.: pathophysiology. In: Marsden, CD, Fahn, S, eds. Movements Disorders. Butterworths International Medical Reviews Neurology 2. London: Butterworth, 1982: 119–126.Google Scholar
2.Obeso, JA, Grandas, F, Vaamonde, J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989; 39 (Suppl 2): 11–19.Google ScholarPubMed
3.Cedarbaum, JM.The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 1989; 12: 147–166.CrossRefGoogle ScholarPubMed
4.Yeh, KC, August, TF, Bush, DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989; 39 (Suppl 2): 25–38.Google ScholarPubMed
5.Curzon, G, Friedel, J, Grier, L, et al. Sustained release levodopa in Parkinsonism, Lancet 1973; 1: 781.CrossRefGoogle ScholarPubMed
6.Laitinen, LV.Slowly absorbed L-dopa preparation in the treatment of parkinsonism. Act Neurol Scand 1973; 49: 331–338.CrossRefGoogle ScholarPubMed
7.Poewe, WH, Lees, AJ, Stern, GM.Treatment of motor fluctuation in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986; 9: 430–439.CrossRefGoogle ScholarPubMed
8.Cedarbaum, JM, Breck, L, Kutt, H, et al. Controlled-release levodopa/carbidopa II. Sinemet CR4 treatment of response fluctuations in Parkinson’s disease. Neurology 1987; 37: 1607–1612.CrossRefGoogle ScholarPubMed
9.Duvoisin, RC.New strategies in dopaminergic therapy of Parkinson’s disease: the use of a controlled-release formulation. Neurology 1989; 39 (Suppl 2): 4–6.Google ScholarPubMed
10.LeWitt, PA, Nelson, MV, Berchou, RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989; 39 (Suppl 2): 45–53.Google ScholarPubMed
11.Wilding, IR, Davis, SS, Melia, CD, et al. Gastrointestinal transit of Sinemet CR in healthy volunteers. Neurology 1989; 39 (Suppl 2): 53–59.Google ScholarPubMed
12.Aarli, JA, Gilhus, NE.Sinemet CR in the treatment of patients with Parkinson’s disease already on long-term treatment with levodopa. Neurology 1989; 39 (Suppl 2): 82–85.Google ScholarPubMed
13.Bush, DF, Liss, CL, Morton, A, et al. An open multicenter long-term treatment evaluation of Sinemet CR. Neurology 1989; 39 (Suppl 2): 101–105.Google ScholarPubMed
14.Deleu, D, Jacques, M, Michotte, Y, et al. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology 1989; 39 (Suppl 2): 88–92.Google ScholarPubMed
15.Goetz, CG, Tanner, CM, Gilley, DW, et al. Development and progression of motor fluctuations and side-effects in Parkinson’s disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology 1989; 39 (Suppl 2): 63–67.Google ScholarPubMed
16.Rinne, UK, Rinne, JO.Treatment of early Parkinson’s disease with controlled-release levodopa preparations. Neurology 1989: 39 (Suppl 2): 78–82.Google ScholarPubMed
17.Rodnitzky, RL, Dickins, QS, Dobson, J.Long-term clinical efficacy of Sinemet CR in patients with Parkinson’s disease. Neurology 1989; 39 (Suppl 2): 92–95Google ScholarPubMed
18.Rondot, P, Ziegler, M, Aymard, N, et al. Effect of controlled-release carbidopa/levodopa on motor performance in advance Parkinson’s disease. Neurology 1989; 39 (Suppl 2): 74–78.Google ScholarPubMed
19.Ulm, G, Gerdes, U, Haagen, K.Experiences with Sinemet CR in the Paracelsus-Elenaklinik. Neurology 1989; 39 (Suppl 2): 85–88.Google Scholar
20.Feldman, RG, Mosbach, PA, Kelly, MR, et al. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson’s disease. Neurology 1989; 39 (Suppl 2): 96–101Google ScholarPubMed
21.Hutton, JT, Morris, JL, Bush, DF, et al. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson’s disease. Neurology 1989; 39 (Suppl 2): 67–72.Google ScholarPubMed
22. Parkinson Study Group. Effect of Deprenyl on the progression of disability in early Parkinson’s disease. New Eng J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar